Biologics to Treat Substance Use Disorders -

Biologics to Treat Substance Use Disorders

Vaccines, Monoclonal Antibodies, and Enzymes

Ivan D. Montoya (Herausgeber)

Buch | Hardcover
XVI, 453 Seiten
2016 | 1st ed. 2016
Springer International Publishing (Verlag)
978-3-319-23149-5 (ISBN)
139,09 inkl. MwSt

This book is a scientific compendium documenting the state of the art in the discovery and development of vaccines, monoclonal antibodies, and enzymes for the treatment of Substance Use Disorders (SUDs). The book gives detailed consideration to some of the most cutting edge topics in addiction medicine, including vaccines for nicotine, cocaine, heroin, and methamphetamine dependence; monoclonal antibodies against cocaine, methamphetamine, and phencyclidine; and the enzymes butyrylcholinesterase and cocaine esterase. In addition, the text covers a wide range of new strategies designed to optimize the development and efficacy of biologics. Unlike any other resource, this book reviews how biologics offer exciting new therapeutic opportunities for various psychiatric conditions.

Written by experts in the field, Biologics to Treat Substance Use Disorders is as an authoritative reference for psychiatrists, psychologists, and all other medical professionals working with patients suffering from Substance Use Disorders.

Ivan D. MontoyaNational Institutes of Health, Bethesda, USA

Introduction.- PART I: Vaccines: Introduction.- Nicotine.- Cocaine.- Heroin.- Metamphetamine.- PART II: Monoclonal antibodies: Introduction.- Cocaine.- Metamphetamine.- PCP.- PART III: Enzymes: Introduction.- Butyrylcholinesterase.- Cocaine Esterase.- PART IV: New strategies to optimize the development of biologics: Adenovirus based vaccines.- Nanotechnology based vaccines.- Protein Nanoparticles.- DNA Scaffolded Vaccines.- Single Hapten Conjugate Therapeutic Vaccine.- Vaccine Adjuvants.- Laser Adjuvant.- Peptide Conjugates & Cytokine Adjuvants.- T. brucei: A Platform for Immunization.- Vaccines for SUDs and HIV infection.- New Monoclonal Antibodies.- Protein Engineered for Controlled Duration of Action.- PART V: Ethical aspects of biologics to treat SUDs.

"The intended audience is psychiatrists, pharmacologists, immunologists, counselors, toxicologists, social workers, addiction specialists, and all medical professionals working with patients with drug addictions. ... This is the first book, and a most comprehensive one, about the research and development of biologics to treat substance use disorders and overdose. Hopefully, biologics will be part of the therapeutic armamentarium that healthcare providers can use in the treatment of their patients with these disorders." (Michael Easton, Doody's Book Reviews, June, 2016)

Erscheint lt. Verlag 6.1.2016
Zusatzinfo XVI, 453 p. 104 illus., 57 illus. in color.
Verlagsort Cham
Sprache englisch
Maße 155 x 235 mm
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
Medizin / Pharmazie Medizinische Fachgebiete Psychiatrie / Psychotherapie
Medizin / Pharmazie Pharmazie
Schlagworte Biologics • Drug Addiction • enzymes • Medicine • monoclonal antibodies • Pharmacology/Toxicology • pharmacotherapy • Psychopharmacology • substance abuse • vaccines
ISBN-10 3-319-23149-9 / 3319231499
ISBN-13 978-3-319-23149-5 / 9783319231495
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich